|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非诺贝特治疗与2型糖尿病患者长期心血管病风险的关系显示文摘2型糖尿病患者心血管病风险高,部分原因在于高三酰甘油和低高密度脂蛋白胆固醇血症。而在他汀类药物治疗基础上,加强降低三酰甘油治疗,能否降低这种风险尚不清楚。该研究的目的是在使用他汀类药物治疗的2型糖尿病患者中,确定非诺贝特能否降低心血管病风险。 | 刘莉 叶鹏 Elam MB Ginsberg HN Lovato LC Corson M Largay J Leiter LA Lopez C O'Connor PJ Sweeney ME Weiss D Friedewald WT Buse JB Gerstein HC Probstfield J Grimm R Ismail-Beigi F Goff DC Jr Fleg JL Rosenberg Y Byington RP ACCORDION study investigators | 2017 | 中华高血压杂志2017，25，6： | 7 |
| 2 | Behavioral medicine for migraine显示文摘 | Buse DC Andrasik F | 2009 | Neurol Clin2009，27，2： | 1 |
| 3 | Exenatide effects on diabe- tes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 4 | Exenatide effects on diabetes, obesity, cardiovascular risk fac tors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | CmT Med Res Opin2008，24，： | 1 |
| 5 | Metabolic effects of two years of exenatide treatment on diabetes,obesity,and hepatic biomarkers in patients with type 2 diabetes:an interim analysis of data from the open-label,uncontrolled extension of three double-blind,placebo-controlled trials显示文摘 | Buse JB Klonof DC Nielsen LL | 2007 | Clin Ther2007，29，1： | 1 |
| 6 | Exenatide effects on dia- betes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curt Med Res Opin2008，24，1： | 1 |
| 7 | Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? 显示文摘 | Lindamer LA Buse DC Lohr JB | 2001 | Biological Psychiatry2001，49，： | 1 |
| 8 | Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bio- markers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials显示文摘 | Buse JB Klonoff DC Nielsen LL | 2007 | Clin Ther2007，29，1： | 1 |
| 9 | Metabolic effeets of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an inter- im analysis of data from the open-label, uncontrolled extension of three double-blind, plaoebo-eontrolled trials 显示文摘 | BUSE JB KLONOFF DC NIELSEN LL | 2007 | Clin Ther2007，29，1： | 1 |
| 10 | Exenatide effects on diabetes,obesity, cardiovascular risk factors and hepatic biomarkers in patientswith type 2 diabetes treated for at least 3 years*显示文摘 | KlonofF DC Buse JB Nielsen LL | 2007 | Current MedicalResearch and Opinion?2007，24，1： | 1 |
| 11 | Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treaed for at least 3years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 12 | Effects of intensive glucose lowering in type 2 diabetes显示文摘 | Goff DC Jr Bigger JT Buse JB | 2008 | N Engl J Med2008，358，24： | 1 |
| 13 | Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 14 | Headache and combination estrogen-progestin oral contraceptives:Integrating evidence,guidelines,and clinical practice显示文摘 | Loder EW Buse DC Golub JR | 2005 | Headache2005，45，： | 1 |
| 15 | Exenatide effects on diabetes,obesity,carsiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 16 | Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2diabetes treated for at least3years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2007 | Current Medical Research and Opinion2007，24，1： | 1 |
| 17 | Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
| 18 | Exenatide effects on dia-betes ,obesity, cardiovascular risk factors and hepatic biomarkersin patients with type 2 diabetes treated for at least 3 years显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Cuit Med Res 0pin2008，24，1： | 1 |
| 19 | Psychiatric comorbidities of episodic and chronic migraine显示文摘 | Buse DC Silberstein SD Manack AN | 2013 | J Neurol2013，260，8： | 1 |
| 20 | Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 显示文摘 | Klonoff DC Buse JB Nielsen LL | 2008 | Curr Med Res Opin2008，24，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员